Trial Profile
An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Ritonavir; Saquinavir
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Pfizer; ViiV Healthcare
- 18 Nov 2010 Additional lead trial centre 'ViiV Healthcare' identified as reported by ClinicalTrials.gov.
- 13 Jan 2010 Actual patient number (30) added as reported by ClinicalTrials.gov.
- 25 Dec 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.